Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 7/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808881 | 1.00 | GNRHR (0.44) | GNRHRMTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL14424672 | 0.89 | GNRHR (0.56) | GNRHR | |
| SCHEMBL6804909 | 0.78 | GNRHR (0.50) | GNRHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14424674 | 0.75 | GNRHR (0.56) | GNRHR | |
| SCHEMBL14424652 | 0.75 | GNRHR (0.61) | GNRHR | |
| SCHEMBL14424650 | 0.72 | GNRHR (0.56) | GNRHR | |
| SCHEMBL14424671 | 0.72 | GNRHR (0.56) | GNRHR | |
| SCHEMBL14424669 | 0.71 | GNRHR (0.57) | GNRHR | |
| SCHEMBL14438214 | 0.71 | GNRHR (0.67) | GNRHR | |
| SCHEMBL5753476 | 0.70 | GNRHR (0.69) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809098-B2 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171354-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171354-A1 | Compounds | GNRHR, LHCGR, FSHR | GNRHR 1/4885MTNR1A 113/4885MTNR1B 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.